Molecure S.A. (MOC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Molecure S.A. (MOC) has a cash flow conversion efficiency ratio of 0.266x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł26.15 Million ≈ $7.20 Million USD) by net assets (zł98.21 Million ≈ $27.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MOC equity to assets ratio to measure how much of total assets are equity-financed.
Molecure S.A. - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Molecure S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MOC cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Molecure S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecure S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
0.712x |
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
-0.445x |
|
Hudson Global Inc
NASDAQ:HSON
|
0.003x |
|
Satria Mega Kencana Tbk PT
JK:SOTS
|
-0.009x |
|
P3 Health Partners Inc
NASDAQ:PIII
|
0.206x |
|
Unite Group PLC
LSE:UTG
|
0.019x |
|
Minehub Technologies Inc
V:MHUB
|
-1.632x |
|
Vection Technologies Ltd
AU:VR1
|
0.003x |
Annual Cash Flow Conversion Efficiency for Molecure S.A. (2015–2024)
The table below shows the annual cash flow conversion efficiency of Molecure S.A. from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Molecure S.A. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł103.41 Million ≈ $28.46 Million |
zł-56.99 Million ≈ $-15.68 Million |
-0.551x | -138.84% |
| 2023-12-31 | zł100.93 Million ≈ $27.78 Million |
zł-23.29 Million ≈ $-6.41 Million |
-0.231x | -185.69% |
| 2022-12-31 | zł126.45 Million ≈ $34.80 Million |
zł-10.21 Million ≈ $-2.81 Million |
-0.081x | +15.53% |
| 2021-12-31 | zł141.14 Million ≈ $38.84 Million |
zł-13.50 Million ≈ $-3.71 Million |
-0.096x | -123.87% |
| 2020-12-31 | zł143.40 Million ≈ $39.47 Million |
zł57.44 Million ≈ $15.81 Million |
0.401x | +545.88% |
| 2019-12-31 | zł79.13 Million ≈ $21.78 Million |
zł-7.11 Million ≈ $-1.96 Million |
-0.090x | -50.45% |
| 2018-12-31 | zł81.89 Million ≈ $22.54 Million |
zł-4.89 Million ≈ $-1.35 Million |
-0.060x | -195.95% |
| 2017-12-31 | zł29.72 Million ≈ $8.18 Million |
zł-599.63K ≈ $-165.03K |
-0.020x | +81.79% |
| 2016-12-31 | zł13.01 Million ≈ $3.58 Million |
zł-1.44 Million ≈ $-396.50K |
-0.111x | -11.67% |
| 2015-12-31 | zł15.43 Million ≈ $4.25 Million |
zł-1.53 Million ≈ $-421.14K |
-0.099x | -- |
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more